ALPHA-TOCOPHEROL (VITAMINE) FOR CONDITIONS ASSOC W/ CHRONIC RENAL INSUFFICIENCY

α-生育酚（维生素）治疗慢性肾功能不全的病症

• 批准号: 7376510
• 负责人: RAJIV SARAN
• 金额: $ 0.82万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376510
• 关键词: antioxidants; blood; chronic renal failure; glycation; kidney; oxidative stress; tocopherols

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic kidney disease (CKD) is associated with a high prevalence of heart disease as a result of narrowing of arteries, a process called atherosclerosis. This disease process is associated with increased production of potentially harmful substances in the blood collectively termed "oxidative stress." It is our hypothesis that antioxidant therapy such as vitamin E may serve to attenuate the oxidative stress that characterizes kidney failure even before the start of dialysis with the potential of ameliorating or at least slowing the progression of this disease process. The intervention that we aim to study is a 3-month course of antioxidant treatment with vitamin E in a dose of 800 IU per day. The groups of patients to be studied are 35 normal controls and 35 patients with advanced chronic kidney disease (non-diabetic). It is not a randomized trial and no placebo control is being used. The outcomes are 1) change in levels of markers of oxidative stress (primary outcome), 2) endothelial function and advanced glycation in the blood (secondary outcomes). Urine will also be tested both at baseline and at end of study to measure markers of oxidative stress, advanced glycation, markers of podocyte (a type of cell in the kidney) injury and routine chemistries. From the results of this study we will draw conclusions regarding the potential role of vitamin E treatment chronic kidney disease, especially before the initiation of dialysis therapy. This may have a bearing on future clinical trials in this patient population.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。慢性肾脏病（CKD）与动脉狭窄导致的心脏病高发相关，这一过程称为动脉粥样硬化。这种疾病的过程与血液中潜在有害物质的产生增加有关，统称为“氧化应激”。“我们的假设是，维生素E等抗氧化剂治疗可能有助于减轻氧化应激，即使在透析开始之前，这种氧化应激也是肾衰竭的特征，有可能改善或至少减缓这种疾病的进展。我们旨在研究的干预措施是每天800 IU剂量的维生素E抗氧化治疗的3个月疗程。待研究的患者组为35名正常对照组和35名晚期慢性肾脏疾病（非糖尿病）患者。这不是一项随机试验，也没有使用安慰剂对照。结果是1）氧化应激标志物水平的变化（主要结果），2）内皮功能和血液中的晚期糖化（次要结果）。还将在基线和研究结束时检测尿液，以测量氧化应激、晚期糖基化的标志物、足细胞（肾脏中的一种细胞）损伤的标志物和常规化学。从这项研究的结果中，我们将得出结论，维生素E治疗慢性肾脏疾病的潜在作用，特别是在透析治疗开始之前。这可能对该患者人群的未来临床试验产生影响。